ERBB2 and metastatic colorectal cancer: Siena Siena S S Di Bartolomeo Di Bartolomeo M M Raghav Raghav K K Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial Lancet Oncol Lancet Oncol 2021 2021 22 22 6 6 779 779 789 789 10.1016/S1470-2045(21)00086-3 10.1016/S1470-2045(21)00086-3 supplied-pmid 33961795?